News

New management team in Axelar AB 15 August 2018
The Board of Axelar AB has appointed Vidar Wendel-Hansen as new Chief Executive Officer at the Annual Meeting on June 20th. Dr Wendel-Hansen holds an MD, PhD from Karolinska Institutet and has more than twenty years’ experience from the life science …
Clinical Trial Application for Phase I trial of AXL1717 new capsule formulation submitted in India 9 January 2018
Since 2015 Axelar AB has had a co-development agreement with Cadila Pharmaceuticals Ltd for collaboration on AXL1717 formulation development and clinical development. Cadila Pharmaceuticals Ltd has developed a new AXL1717 formulation in 25 & 50 …
Axelar attends BIO-Europe partnering conference in Berlin, Germany 6 November 2017
Axelar AB will attend the 23rd annual BIO-Europe conference in Berlin, Germany on November 6-8, 2017 to meet with potential partners and investors. The BIO-Europe conference is Europe's largest partnering conference serving the global biotechnology …
Axelar attends BIO Investor Forum in San Francisco, USA 17 October 2017
Axelar AB will attend the BIO Investor Forum in San Francisco, USA on October 17-18, 2017 to meet with potential partners and investors. The BIO Investor Forum is an international biotech investor conference focused on early and established private …
Axelar AB welcomes Vidar Wendel-Hansen as Chief Medical Officer 1 September 2017
Vidar Wendel-Hansen has more than twenty years’ experience from pre-clinical and clinical development. He has served as Medical Director in both small biotech and large pharmaceutical companies. Dr Wendel-Hansen is also former Clinical Assessor at …
FDA Grants Orphan Drug Designation for AXL1717 for the Treatment of Glioma 28 July 2017
Axelar AB, a pharmaceutical company focused on developing targeted oral anti-cancer therapies for indications where there are significant unmet medical needs, announced today that the U.S. Food and Drug Administration (FDA) has granted an orphan …
EMA Grants Axelar Orphan Drug Designation for AXL1717 for the Treatment of Glioma 25 July 2017
Axelar AB today announced that the European Medicines Agency (EMA) has granted orphan designation to Axelar's drug candidate AXL1717 for the treatment of glioma. The EMA's orphan designation program is intended to encourage the development of …
Axelar attended 2017 BIO International Convention in San Diego, USA 26 June 2017
Axelar AB attended the 2017 BIO International Convention June 19-22 in San Diego, USA to meet with potential partners and investors. During the convention there were 16 123 attendees from 74 countries and 3 500 participating organizations took part …
Axelar attends BIO-Europe Spring partnering conference in Stockholm, Sweden 4 April 2016
Axelar AB will attend when the tenth annual BIO-Europe Spring conference Stockholm, Sweden on April 4–6, 2016 to meet with potential partners and investors. This is a partnering conference for the biotechnology industry and the conference annually …
Axelar and Cadila Pharmaceuticals announce co-development agreement for Non-Small Cell Lung Cancer Treatment. 20 August 2015
STOCKHOLM – 20 August 2015: Axelar AB ('Axelar') and Cadila Pharmaceuticals Sweden AB (‘Cadila Pharma') today announced that they have entered into a co-development agreement for further formulation development and clinical development of AXL1717 in …
The Foundation for Baltic and East European Studies (Östersjöstiftelsen) has purchased all KDev Investments AB shares in Axelar AB for an undisclosed up-front payment and earn-out payments. 8 April 2015
This deal was made as KDev Investments wanted to divest its entire holding to one party. Östersjöstiftelsen will offer the other shareholders in Axelar AB the opportunity to purchase shares pro-rata, as Östersjöstiftelsen, according to their …

Archive

Go back